Murata M, Miyashita S, Yokoo C, Tamai M, Hanada K, Hatayama K, Towatari T, Nikawa T, Katunuma N
Research Center, Taisho Pharmaceutical Co., Saitama, Japan.
FEBS Lett. 1991 Mar 25;280(2):307-10. doi: 10.1016/0014-5793(91)80318-w.
A series of new epoxysuccinyl peptides were designed and synthesized to develop a specific inhibitor of cathepsin B. Of these compounds, N-(L-3-trans-ethoxycarbonyloxirane-2-carbonyl)-L-isoleucyl-L-proli ne (compound CA-030) and N-(L-3-trans-propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-prol ine (compound CA-074) were the most potent and specific inhibitors of cathepsin B in vitro. The carboxyl group of proline and the ethyl ester group or the n-propylamide group in the oxirane ring were necessary, the ethyl ester group or the n-propylamide group being particularly effective for distinguishing cathepsin B from other cysteine proteinases such as cathepsins L and H, and calpains.
设计并合成了一系列新型环氧琥珀酰肽,以开发组织蛋白酶B的特异性抑制剂。在这些化合物中,N-(L-3-反式-乙氧基羰基环氧乙烷-2-羰基)-L-异亮氨酰-L-脯氨酸(化合物CA-030)和N-(L-3-反式-丙基氨基甲酰基环氧乙烷-2-羰基)-L-异亮氨酰-L-脯氨酸(化合物CA-074)是体外组织蛋白酶B最有效和最具特异性的抑制剂。脯氨酸的羧基以及环氧乙烷环中的乙酯基或正丙酰胺基是必需的,乙酯基或正丙酰胺基对于区分组织蛋白酶B与其他半胱氨酸蛋白酶(如组织蛋白酶L和H以及钙蛋白酶)特别有效。